Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Third Harmonic Bio, Inc. THRD NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
68/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$16.15
+200.2%

Third Harmonic Bio, Inc. (THRD) is a Biotechnology company in the Healthcare sector, currently trading at $5.38. It has a SharesGrow Score of 66/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is THRD = $16 (+200.2% upside).

Net income is $45M, growing at +79.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $3M against $285M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 40.87 (strong liquidity). Debt-to-assets is 1.1%. Total assets: $295M.

Analyst outlook: 1 / 5 analysts rate THRD as buy (20%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 52/100 (Partial), Income ?/100 (Fail).

$16.15
▲ 200.19% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for Third Harmonic Bio, Inc., the average price target is $16.15, with a high forecast of $23.00, and a low forecast of $3.60.
Highest Price Target
$23.00
Average Price Target
$16.15
Lowest Price Target
$3.60

THRD SharesGrow Score Overview

68/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — THRD

✓
VALUE Pass
100/100
THRD trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $16, implying +197.4% from the current price $5. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
THRD: +0%/yr revenue is, +79.5%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
THRD: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet THRD: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 40.87 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
THRD: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 1 / 5 analysts rate THRD as buy (20%). Analyst consensus target is $16 (+197.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range3.18-16.02
Volume1.42M
Avg Volume (30D)262.78K
Market Cap$242.79M
Beta (1Y)2.13
Share Statistics
EPS (TTM)1.09
Shares Outstanding$41.73M
IPO Date2022-09-14
Employees31
CEONatalie C. Holles
Financial Highlights & Ratios
EBITDA$-45.42M
Net Income$45.47M
Operating Income$58.87M
Total Cash$285.06M
Total Debt$3.21M
Net Debt$-281.86M
Total Assets$294.61M
Price / Earnings (P/E)4.9
Analyst Forecast
1Y Price Target$19.00
Target High$23.00
Target Low$3.60
Upside+253.2%
Rating ConsensusHold
Analysts Covering5
Buy 20% Hold 80% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS88427A1079

Price Chart

Track all markets on TradingView
THRD
Third Harmonic Bio, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
3.18 52WK RANGE 16.02

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.35
+0.70%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 MACK
MACK
Merrimack Pharmaceuticals, Inc.
$15.15
+0.10%
 GRPH
GRPH
Graphite Bio, Inc.
$3.18
-2.75%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message